28788-62-7

Basic information

• Product Name: 4-N-BUTYLBENZOYL CHLORIDE
• Synonyms: 4-Butylbenzoic acid chloride;4-Butylbenzoyl chloride,99%;4-(But-1-yl)benzoyl chloride;4-N-BUTYLBENZOYL CHLORIDE;4-BUTYLBENZENE-1-CARBONYL CHLORIDE;4-BUTYLBENZOYL CHLORIDE;P-BUTYLBENZOYL CHLORIDE;4-butyl-benzoylchlorid
• CAS NO: 28788-62-7
• Molecular Formula: C₁₁H₁₃ClO
• Molecular Weight: 196.67
• EINECS: 249-224-2
• Product Categories: Building Blocks for Liquid Crystals;Chalcones, etc. (Building Blocks for Liquid Crystals);Functional Materials;Acid Halides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 28788-62-7.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 155-156 °C22 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: clear slightly yellow liquid
• Density: 1.051 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.00655mmHg at 25°C
• Refractive Index: n20/D 1.5351(lit.)
• Water Solubility: Reacts with water.
• Sensitive: Moisture Sensitive
• CAS DataBase Reference: 4-N-BUTYLBENZOYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-N-BUTYLBENZOYL CHLORIDE(28788-62-7)
• EPA Substance Registry System: 4-N-BUTYLBENZOYL CHLORIDE(28788-62-7)

Safety Data

• Hazard Codes: C
• Statements: 34-36/37
• Safety Statements: 26-27-28-36/37/39-45
• RIDADR: UN 3265 8/PG 2
• WGK Germany: 3
• TSCA: Yes
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 28788-62-7(Hazardous Substances Data)

Usage

Chemical Properties

CLEAR SLIGHTLY YELLOW LIQUID

Uses

Different sources of media describe the Uses of 28788-62-7 differently. You can refer to the following data:
1. 4-Butylbenzoyl chloride was used in the synthesis of 2,5-bis[(4-butylbenzoyl)oxy]styrene (BBOS, monomer).
2. Intermediates of Liquid Crystals

InChI:InChI=1/C11H13ClO/c1-2-3-4-9-5-7-10(8-6-9)11(12)13/h5-8H,2-4H2,1H3

Upstream product

• 201230-82-2 carbon monoxide 
• 41492-05-1 p-bromobutylbenzene 
• 20651-71-2 4-butyl benzoic acid 
• 79-37-8 oxalyl dichloride 
• 104-51-8 1-butylbenzene 

Downstream Products

• 111028-85-4 4'-butyl-2,3,5,6-tetramethyl-benzophenone 
• 107377-07-1 4-n-butylbenzamide 
• 64357-88-6 (4-Butyl-phenyl)-(4-nonyl-phenyl)-methanone 
• 123769-41-5 (4-Butyl-phenyl)-(3,4-dihydro-2H-benzo[b][1,4]dioxepin-7-yl)-methanone 
• 1200-14-2 4-(n-butyl)benzaldehyde 
• 104252-83-7 2-(4-Butyl-benzoylamino)-pentanedioic acid 
• 122020-56-8 4-Butyl-N-((Z)-octadec-9-enyl)-benzamide 
• 92002-57-8 1,4-bis-(4-butyl-benzoylamino)-anthraquinone 
• 152241-49-1 2,5-bis<(4-butylbenzoyl)oxy>styrene 
• 147299-38-5 8-<4-(4-n-butylbenzoyl)phenyl>octanoic acid methyl ester 
• 79877-16-0 4-Butyl-benzoic acid 2-(4-butyl-phenyl)-4-oxo-4H-benzo[d][1,3]oxazin-6-yl ester 
• 115732-26-8 N-(4-n-butylbenzoyl)-D-phenylalanine 
• 143330-08-9 5-(4-Butyl-benzoylamino)-isophthalic acid 
• 132668-03-2 4-Butyl-benzoic acid 4-(5-nonyl-[1,3,4]thiadiazol-2-yl)-phenyl ester 

Relevant articles and documents

O-Alkyl Hydroxamates Display Potent and Selective Antileishmanial Activity

Leishmania (L.) infantum causes visceral, cutaneous, and mucosal leishmaniasis in humans and canine leishmaniasis in dogs. Herein, we describe that O-alkyl hydroxamate derivatives displayed potent and selective in vitro activity against the amastigote stage of L. infantum while no activity was observed against promastigotes. Compound 5 showed potent in vivo activity against L. infantum. Moreover, the combination of compound 5 supported on gold nanoparticles and meglumine antimoniate was also effective in vivo and improved the activity of these compounds compared to that of the individual treatment. Docking studies showed that compound 5 did not reach highly conserved pocket C and established interactions with the semiconserved residues V44, A45, R242, and E243 in pocket A of LiSIR2rp1. The surface space determined by these four amino acids is not conserved in human sirtuins. Compound 5 represents a new class of selective ligands with antileishmanial activity.

Ni-Catalyzed Direct Carboxylation of Aryl C?H Bonds in Benzamides with CO2

The direct carboxylation of inert aryl C?H bond catalyzed by abundant and cheap nickel is still facing challenge. Herein, we report the Ni-catalyzed direct carboxylation of aryl C?H bonds in benzamides under 1 atm of CO2 to afford various methyl carboxylates or phthalimides, dealing with different post-processing. The reaction displays excellent functional group tolerance and affords moderate to high carboxylation yields under mild conditions. Detail mechanistic studies suggest that a Ni(0)?Ni(II)?Ni(I) catalytic cycle may be involved in this reaction. (Figure presented.).

Myobacterium Tuberculosis-Thioredoxin Reductase Inhibitor as an Antitubercular Agent

The invention relates to Mycobacterium tuberculosis-thioredoxin reductase inhibitors, processes for the preparation thereof, drugs containing said compounds, and the use of said compounds for manufacturing drugs.